416 related articles for article (PubMed ID: 24729444)
1. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.
Warnke C; von Geldern G; Markwerth P; Dehmel T; Hoepner R; Gold R; Pawlita M; Kümpfel T; Mäurer M; Stangel M; Wegner F; Hohlfeld R; Straeten V; Limmroth V; Weber T; Hermsen D; Kleinschnitz C; Hartung HP; Wattjes MP; Svenningson A; Major E; Olsson T; Kieseier BC; Adams O
Ann Neurol; 2014 Dec; 76(6):792-801. PubMed ID: 24729444
[TBL] [Abstract][Full Text] [Related]
2. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
[TBL] [Abstract][Full Text] [Related]
3. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Plavina T; Subramanyam M; Bloomgren G; Richman S; Pace A; Lee S; Schlain B; Campagnolo D; Belachew S; Ticho B
Ann Neurol; 2014 Dec; 76(6):802-12. PubMed ID: 25273271
[TBL] [Abstract][Full Text] [Related]
4. The effect of plasma exchange on serum anti-JC virus antibodies.
Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
[TBL] [Abstract][Full Text] [Related]
5. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
[TBL] [Abstract][Full Text] [Related]
6. JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab.
Ryschkewitsch CF; Jensen PN; Monaco MC; Major EO
Ann Neurol; 2010 Sep; 68(3):384-91. PubMed ID: 20818792
[TBL] [Abstract][Full Text] [Related]
7. Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification.
Laroni A; Giacomazzi CG; Grimaldi L; Gallo P; Sormani MP; Bertolotto A; McDermott JL; Gandoglia I; Martini I; Vitello G; Rinaldi F; Barzon L; Militello V; Pizzorno M; Bandini F; Capello E; Palù G; Uccelli A; Mancardi GL; Varnier OE
J Neuroimmune Pharmacol; 2012 Sep; 7(3):665-72. PubMed ID: 22585413
[TBL] [Abstract][Full Text] [Related]
8. JCV detection in multiple sclerosis patients treated with natalizumab.
Sadiq SA; Puccio LM; Brydon EW
J Neurol; 2010 Jun; 257(6):954-8. PubMed ID: 20052484
[TBL] [Abstract][Full Text] [Related]
9. Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS.
Kuhle J; Gosert R; Bühler R; Derfuss T; Sutter R; Yaldizli O; Radue EW; Ryschkewitsch C; Major EO; Kappos L; Frank S; Hirsch HH
Neurology; 2011 Dec; 77(23):2010-6. PubMed ID: 22076540
[TBL] [Abstract][Full Text] [Related]
10. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.
Villar LM; Costa-Frossard L; Masterman T; Fernandez O; Montalban X; Casanova B; Izquierdo G; Coret F; Tumani H; Saiz A; Arroyo R; Fink K; Leyva L; Espejo C; Simó-Castelló M; García-Sánchez MI; Lauda F; Llufriú S; Álvarez-Lafuente R; Olascoaga J; Prada A; Oterino A; de Andrés C; Tintoré M; Ramió-Torrentà L; Rodríguez-Martín E; Picón C; Comabella M; Quintana E; Agüera E; Díaz S; Fernandez-Bolaños R; García-Merino JA; Landete L; Menéndez-González M; Navarro L; Pérez D; Sánchez-López F; Serrano-Castro PJ; Tuñón A; Espiño M; Muriel A; Bar-Or A; Álvarez-Cermeño JC
Ann Neurol; 2015 Mar; 77(3):447-57. PubMed ID: 25581547
[TBL] [Abstract][Full Text] [Related]
11. Comparison of qPCR with ddPCR for the Quantification of JC Polyomavirus in CSF from Patients with Progressive Multifocal Leukoencephalopathy.
Ngouth N; Monaco MC; Walker L; Corey S; Ikpeama I; Fahle G; Cortese I; Das S; Jacobson S
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746716
[TBL] [Abstract][Full Text] [Related]
12. Changes to anti-JCV antibody levels in a Swedish national MS cohort.
Warnke C; Ramanujam R; Plavina T; Bergström T; Goelz S; Subramanyam M; Kockum I; Rahbar A; Kieseier BC; Holmén C; Olsson T; Hillert J; Fogdell-Hahn A
J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1199-205. PubMed ID: 23463870
[TBL] [Abstract][Full Text] [Related]
13. A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JCV testing.
Mazda ME; Brosch JR; Wiens AL; Bonnin JM; Kamer AP; Mattson DH; Snook RJ
Int J Neurosci; 2013 May; 123(5):353-7. PubMed ID: 23252596
[TBL] [Abstract][Full Text] [Related]
14. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.
Rudick RA; O'Connor PW; Polman CH; Goodman AD; Ray SS; Griffith NM; Jurgensen SA; Gorelik L; Forrestal F; Sandrock AW; Goelz SE
Ann Neurol; 2010 Sep; 68(3):304-10. PubMed ID: 20737514
[TBL] [Abstract][Full Text] [Related]
15. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I
Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
[TBL] [Abstract][Full Text] [Related]
16. Improving detection of JC virus by ultrafiltration of cerebrospinal fluid before polymerase chain reaction for the diagnosis of progressive multifocal leukoencephalopathy.
Nakamichi K; Kawamoto M; Ishii J; Saijo M
BMC Neurol; 2019 Oct; 19(1):252. PubMed ID: 31653203
[TBL] [Abstract][Full Text] [Related]
17. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
[TBL] [Abstract][Full Text] [Related]
18. Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish Multiple Sclerosis patients treated with natalizumab.
Dominguez-Mozo MI; Garcia-Montojo M; De Las Heras V; Garcia-Martinez A; Arias-Leal AM; Casanova I; Arroyo R; Alvarez-Lafuente R
J Neuroimmune Pharmacol; 2013 Dec; 8(5):1277-86. PubMed ID: 23979860
[TBL] [Abstract][Full Text] [Related]
19. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.
Perkins MR; Ryschkewitsch C; Liebner JC; Monaco MC; Himelfarb D; Ireland S; Roque A; Edward HL; Jensen PN; Remington G; Abraham T; Abraham J; Greenberg B; Kaufman C; LaGanke C; Monson NL; Xu X; Frohman E; Major EO; Douek DC
PLoS Pathog; 2012; 8(11):e1003014. PubMed ID: 23144619
[TBL] [Abstract][Full Text] [Related]
20. Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive.
Fragoso YD; Mendes MF; Arruda WO; Becker J; Brooks JB; Carvalho Mde J; Comini-Frota ER; Domingues RB; Ferreira ML; Finkelsztejn A; Gama PD; Gomes S; Gonçalves MV; Kaimen-Maciel DR; Morales Rde R; Muniz A; Ruocco HH; Salgado PR; Albuquerque LB; Gama RA; Georgeto S; Lopes J; Oliveira CL; Oliveira FT; Safanelli J; Saldanha PC; Satomi M
Arq Neuropsiquiatr; 2013 Oct; 71(10):780-2. PubMed ID: 24212514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
